Selected pharmacokinetic parameters for cefovecin in hens and green iguanas
Thuesen, Line Risager; Bertelsen, Mads Frost; Brimer, Leon; Skaanild, Mette Tingleff

Publication date:
2009

Document Version
Publisher's PDF, also known as Version of record

Citation for published version (APA):
Thuesen, L. R., Bertelsen, M. F., Brimer, L., & Skaanild, M. T. (2009). Selected pharmacokinetic parameters for cefovecin in hens and green iguanas. Poster session presented at European Association for Veterinary Pharmacology and Toxicology, Leipzig, Germany.
Selected Pharmacokinetic Parameters for Cefovecin
In Hens and Green Iguanas

Introduction

• Cefovecin (ConveniaTM, Pfizer Animal Health) is a semi-synthetic 3rd generation cephalosporin recently developed for use in dogs and cats.
• Cefovecin has in previous studies been shown to have an exceptional long elimination half-life in dogs (136 ± 10 h) and cats (166 ± 18 h), making it suitable for antibacterial treatment with a 14-day dosing interval in these species.
• A single-injection treatment will reduce stress in animal species sensitive to stress from handling and restraint such as reptiles and birds.
• The aim of this study was therefore to determine the plasma-half-life for cefovecin in hens and green iguanas to establish whether cefovecin is a suitable antibiotic for single-injection treatment of bacterial infections in these species.

Materials and methods

Pharmacokinetic parameters for hens were determined following subcutaneous and injections with 10 mg cefovecin/kg bodyweight in 8 juvenile Lohmann hens.
• After injection 9 blood samples were taken from each hen at 0, 5, 10, 15, 20, 30, 40, 60, 90, and 120 minutes after injection.

Pharmacokinetic parameters for green iguanas were determined following subcutaneous injections with 10 mg cefovecin/kg bodyweight in 16 juvenile green iguanas of unknown origin.
• Samples were taken at times 7, 11, 18 min. after injection each time from 2 iguanas. Then the 16 iguanas were divided into 4 groups. At the times 20 min., 1, 4, 8, 16, and 24 h. after injection, blood samples were drawn from one of the groups after a rotation scheme.

A number of preliminary studies in randomly selected species of birds and reptiles were performed to investigate whether the pharmacokinetics found in hens and green iguanas were representative for these classes of animals.

All blood samples were analysed by HPLC using the following method developed by us:
• Proteins in plasma samples were precipitated with 35% Trichloroacetic acid (3:1) and samples were centrifuged.
• Supernatant was injected for HPLC analysis.
• The mobile fase consisted of 15% Acetonitrile and 85% 10mM Ammonium acetate pH 3.
• The column used was a Supelcosil LC-B DB (3 µm) (3.3 cm x 4.6 mm) column (Supelco).
• Components detected at wavelength 280 nm.

Results

Pharmacokinetic parameters for cefovecin in hens
• Cefovecin was characterized by rapid absorption with peak plasma concentration of 6 ± 2 µg/mL within 20 min. of subcutaneous injection.
• Mean plasma half-life was 52 ± 16 minutes after subcutaneous injection.
• Volume of distribution was 1.6 ± 0.5 L/kg and clearance was 21 ± 3 mL/min/Kg (Both parameters calculated with the bioavailability set to be 100%)

Pharmacokinetic parameters for cefovecin in green iguanas
• Mean plasma half-life was 3.9 hours after subcutaneous injection.
• Volume of distribution was 0.3 L/hr/Kg after subcutaneous injection (Parameters calculated with the bioavailability set to be 100%)

Discussion

• Concentrations of cefovecin in plasma obtained from bird species in the preliminary study were similar to concentrations in hens.
• More dissimilarities were observed between reptile species, indicating a larger variance in pharmacokinetic parameters in these species.
• Possible reasons for variation of pharmacokinetics for cefovecin in different species include:
  • diversity in P450 isoenzymes
  • variations in protein binding
  • renal physiologic and anatomic differences
• There is still a good possibility that there are other stress sensitive animal species for which cefovecin will be a good choice for antibiotic treatment.
• There is a need to identify broad-spectrum antibiotics with long elimination half-lives that can be used in wildlife and zoo animals to reduce the stress these animals experience in relation to medical care.

Conclusion

• Cefovecin is not suitable for treatment of bacterial infections with a single-injection dosing regime in hens or green iguanas.
• It is unlikely that cefovecin is suitable for treatment of bacterial infections in any species of birds.
• Cefovecin may be indicated for treatment in some but not all species of reptiles.
• More studies on cefovecin are needed.

References: